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Summary
Introduction: Azithromycin (AZM) and other macrolide antibiotics are applied as im‐
munomodulatory treatments for CNS disorders. The immunomodulatory and antibi‐
otic properties of AZM are purportedly independent.
Aims: To improve the efficacy and reduce antibiotic resistance risk of AZM‐based
therapies, we evaluated the immunomodulatory and neuroprotective properties of
novel AZM derivatives. We semisynthetically prepared derivatives by altering sugar
moieties established as important for inhibiting bacterial protein synthesis. Bone mar‐
row‐derived macrophages (BMDMs) were stimulated in vitro with proinflammatory,
M1, stimuli (LPS + INF‐gamma) with and without derivative costimulation. Pro‐ and
anti‐inflammatory cytokine production, IL‐12 and IL‐10, respectively, was quantified
using ELISA. Neuron culture treatment with BMDM supernatant was used to assess
derivative neuroprotective potential.
Results: Azithromycin and some derivatives increased IL‐10 and reduced IL‐12 pro‐
duction of M1 macrophages. IL‐10/IL‐12 cytokine shifts closely correlated with the
ability of AZM and derivatives to mitigate macrophage neurotoxicity.
Conclusions: Sugar moieties that bind bacterial ribosomal complexes can be modi‐
fied in a manner that retains AZM immunomodulation and neuroprotection. Since
the effects of BMDMs in vitro are predictive of CNS macrophage responses, our re‐
sults open new therapeutic avenues for managing maladaptive CNS inflammation
and support utilization of IL‐10/12 cytokine profiles as indicators of macrophage po‐
larization and neurotoxicity.
KEYWORDS

brain, erythromycin, M2, microglia, spinal cord injury, stroke

1 | I NTRO D U C TI O N

system (CNS) in conditions such as ischemic brain damage, spinal
cord injury, and traumatic brain injury. After spinal cord injury, for

The management of maladaptive inflammation is an emerging ther‐

example, there is a heterogeneous neuroinflammatory response me‐

apeutic target for many neuropathologies. Different macrophage

diated by resident microglia and infiltrating macrophages. Classically

phenotypes have been identified in the injured central nervous

activated macrophages (M1) secrete proinflammatory cytokines and
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chemokines and contribute to continued cell death and a persistent
1,2

inflammatory microenvironment within the injured spinal cord.

In

contrast, alternatively activated macrophages (M2) release anti‐in‐
flammatory cytokines and facilitate tissue repair. 2 Increasingly, cli‐
nicians and researcher are testing the therapeutic potential of drugs
that polarize macrophage activation toward reparative phenotypes
in a variety of CNS disorders.
Macrolide antibiotics are a class of natural products consisting of
a highly substituted macrocyclic 14‐, 15‐, or 16‐membered lactone
ring. Azithromycin (AZM) is a 15‐membered, second generation,
synthetic derivative of erythromycin with improved pharmacoki‐
netic properties and a broad antimicrobial spectrum.3 Azithromycin
is well tolerated and commonly prescribed. Moreover, AZM be‐
comes highly concentrated in macrophages and other phagocytes.4,5
Across a variety of inflammatory conditions, AZM attenuates proin‐
flammatory cytokine production by macrophages and other immune
cells.6
Azithromycin and other macrolide antibiotics are now
being tested as immunomodulatory agents for CNS disorders.
Specifically, we and others observed immunomodulatory effects
and improved recovery with AZM treatment in spinal cord injury,
stroke, and retinal ischemia/reperfusion injury.7-12 The neuropro‐
tective properties of AZM in these models are associated with
direct effects on macrophages.7-9 We have shown that in vitro
application of AZM to proinflammatory M1 bone marrow‐derived
macrophages (BMDMs) dampens the release of proinflammatory
cytokines, increases M2‐associated anti‐inflammatory cytokines,
and reduces the neurotoxicity of M1 macrophage‐conditioned
medium.7
In efforts to improve efficacy and/or reduce the risk of in‐
creasing antibiotic resistance, researchers are evaluating the
immunomodulatory potential of AZM derivatives and other mac‐
rolide derivatives with the goal of separating the antibiotic from
immunomodulatory properties. As a result, some macrolide de‐
rivatives have been shown to retain immunomodulatory proper‐
ties in models of lung inflammation, inflammatory bowel diseases,
arthritis, and skin inflammation.13-18 The ability of macrolide de‐
rivatives to reduce macrophage‐mediated neurotoxicity, however,
is unknown. With the increased use of AZM as an immunomod‐
ulatory agent for macrophage‐mediated neurotoxicity in CNS pa‐
thologies, our goal in the present study was to determine whether
macrolide derivatives retain neuroprotective properties. Using a
semisynthetic approach to target modification of the sugar moi‐
eties of AZM, we generated a small library of derivatives, some of
which lacked the cladinose found in the parent. We then tested
the cytokine profiles and neurotoxicity of M1‐stimulated BMDMs
treated with derivatives and observed that unique derivatives re‐
duce M1‐macrophage activation and subsequent neuron death.
Previously we determined that the effect of BMDMs in vitro is
predictive of macrophage responses in the injured CNS 8,19,20 ;
therefore, the results of the current study open new therapeutic
avenues for the management of maladaptive inflammation in CNS
disorders.

2 | M E TH O DS
2.1 | Semisynthesis of AZM derivatives
Like other macrolides, AZM inhibits bacterial protein synthesis by
binding to the 50S subunit of ribosome and thus interfering with
the growth of the polypeptide chain. 21,22 Specifically, the sugar
moieties are known to play an essential role in establishing bind‐
ing interactions with the bacterial ribosomal assembly. We used a
semisynthetic approach to create derivatives with targeted altera‐
tions in these bacterial binding sugar residues. The AZM derivatives
that were synthesized and structurally confirmed by spectroscopic
analysis are listed in Table 1. See Supporting information for mass
and H NMR spectrum profiles.
AZM 1: The removal of the cladinose of AZM followed a previously
described procedure.23 Briefly, AZM (6.67 mmol) was dissolved into
200 mL of methanol containing 1% of conc. HCl, and the solution was
stirred at room temperature for 24 hours Saturated NaHCO3 solution
was added to neutralilze the solution, and the solvent was removed
under vacuum. The product was purified by flash column chromatogra‐
phy with silica gel (EtOAc/MeOH) to give AZM1 (5.53 mmol). MS (ESI)
m/z: [M + H]+ calcd for C30H59N2O9 591.4; found 591.4.
AZM4: AZM1 (4.00 mmol) was dissolved into 100 mL anhydrous
ethyl acetate. Acetic anhydride (3.67 mL, 40.0 mmol) was added, and
the solution was stirred for 2 hours at room temperature. The mix‐
ture was washed twice with NaHCO3 (5% in water, 30 mL), and the
organic phase was dried under vacuum. The product was purified by
flash column chromatography with silica gel (DCM/MeOH) to give
AZM2 (3.22 mmol). AZM2 (2.0 mmol) was dissolved into 40 mL an‐
hydrous acetone solution on ice, and 2.0 mL Jones reagent was added
dropwise. After 30 minutes, 10 mL of methanol and 10 mL saturated
NaHCO3 solutions were added and the solid precipitate was col‐
lected by filtration and dried under vacuum. The product was puri‐
fied by flash column chromatography with silica gel (DCM/MeOH) to
give AZM3 (1.30 mmol). AZM3 (1.0 mmol) was dissolved into 30 mL
methanol, and sodium methoxide (5.0 mmol) with 5 mL of water was
added. The solution was stirred at room temperature for 3 hours, and
the solvent was removed under vacuum. The product was purified
by flash column chromatography with silica gel (DCM/MeOH) to
give 0.44 g AZM4 (0.75 mmol). 1H NMR (400 MHz, Methanol‐d4) δ
5.47 (s, 1H), 4.98 (dd, J = 9.8, 3.0 Hz, 1H), 4.16 (d, J = 7.4 Hz, 1H), 3.78
(d, J = 9.9 Hz, 1H), 3.65 (s, 1H), 3.55 (ddd, J = 11.0, 6.1, 1.9 Hz, 2H),
3.30‐3.23 (m, 1H), 3.02 (d, J = 12.3 Hz, 1H), 2.79 (q, J = 7.1 Hz, 1H),
2.60 (ddd, J = 12.2, 10.2, 4.2 Hz, 1H), 2.32 (s, 6H), 2.22 (d, J = 2.2 Hz,
3H), 2.20 (d, J = 2.9 Hz, 1H), 1.98 (d, J = 10.6 Hz, 1H), 1.85 (ddd,
J = 11.5, 7.5, 3.9 Hz, 3H), 1.72 (ddd, J = 12.8, 4.2, 2.0 Hz, 2H), 1.46
(d, J = 14.7 Hz, 1H), 1.37 (s, 3H), 1.33‐1.26 (m, 2H), 1.24 (d, J = 4.5 Hz,
1H), 1.19 (td, J = 10.5, 10.1, 7.2 Hz, 9H), 1.07 (d, J = 6.7 Hz, 5H), 1.00
(d, J = 6.6 Hz, 3H), 0.87 (dd, J = 8.4, 6.5 Hz, 3H). 13C NMR (101 MHz,
Methanol‐d4) δ 174.43, 106.50, 104.20, 93.68, 82.68, 70.25, 68.82,
64.29, 64.17, 61.12, 53.40, 48.44, 45.18, 43.74, 39.56, 30.86, 28.80,
25.39, 20.08, 20.04, 16.14, 15.22, 11.01, 10.87, 9.78, 9.42, 7.46. MS
(ESI) m/z: [M + H]+ calcd for C30H57N2O9 589.4; found 589.4.
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Structure, molecular weight, and antibiotic properties of derivatives
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(Continued)

Derivatives name

Structure

AZM7

N
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674.44
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OH
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Molecular weight

N
O

OH

Minimum inhibitory concentration against Staphylococcus aureus subsp aureus Rosenbach (ATCC 6538).

AZM5: AZM (2.0 mmol) was dissolved into 50 mL anhydrous

1H), 4.62‐4.55 (m, 1H), 4.45 (dd, J = 9.7, 2.0 Hz, 1H), 3.88 (s, 1H),

dimethylene chloride. Acetic anhydride (1.88 mL, 20.0 mmol) was

3.66 (d, J = 2.1 Hz, 1H), 3.60‐3.52 (m, 2H), 3.22 (s, 3H), 3.18 (s,

added, and the solution was stirred for 1 hour The mixture was

1H), 2.94 (t, J = 9.6 Hz, 1H), 2.69 (dddt, J = 14.3, 11.0, 6.9, 3.9 Hz,

washed twice with NaHCO3 (5% in water, 30 mL), and the organic

2H), 2.57 (t, J = 7.1 Hz, 1H), 2.37 (s, 1H), 2.23 (s, 6H), 2.09 (s, 3H),

phase was dried under vacuum. The product was purified by flash

2.06 (s, 3H), 2.02 (s, 3H), 1.82‐1.76 (m, 2H), 1.76‐1.68 (m, 2H),

column chromatography with silica gel (EtOAc/MeOH) to give 1.16 g

1.38‐1.31 (m, 2H), 1.30‐1.24 (m, 6H), 1.24‐1.20 (m, 6H), 1.19 (d,

AZM5 (1.39 mmol). 1H NMR (400 MHz, Methanol‐d4) δ 5.48 (s,

J = 5.2 Hz, 4H), 0.98 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.9 Hz, 2H),

0H), 5.09 (d, J = 4.7 Hz, 1H), 5.00 (dd, J = 10.4, 2.5 Hz, 1H), 4.97 (d,

0.91 (d, J = 7.2 Hz, 2H), 0.85 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz,

J = 4.7 Hz, 1H), 4.71 (d, J = 4.3 Hz, 1H), 4.69‐4.61 (m, 2H), 4.42‐4.30

Chloroform‐d) δ 169.96, 109.99, 101.25, 99.81, 98.81, 97.54,

(m, 2H), 4.16 (dd, J = 5.0, 1.9 Hz, 1H), 4.10 (dd, J = 6.8, 2.5 Hz, 1H),

78.04, 76.36, 75.46, 74.90, 73.96, 71.46, 70.85, 69.36, 64.44,

3.94‐3.77 (m, 2H), 3.62 (dd, J = 6.4, 3.1 Hz, 1H), 3.59 (d, J = 1.9 Hz,

63.32, 60.36, 56.28, 49.01, 40.63, 37.75, 30.45, 26.15, 25.29,

1H), 3.42 (ddd, J = 10.7, 7.2, 3.6 Hz, 1H), 3.36 (d, J = 10.2 Hz, 3H),

21.37, 21.11, 21.01, 20.96, 20.91, 20.43, 18.17, 14.16. MS (ESI)

3.27‐3.14 (m, 2H), 2.96‐2.89 (m, 1H), 2.89‐2.82 (m, 1H), 2.73 (d,

m/z: [M + H]+ calcd for C 34H63N2O11 675.4, found 675.4.

J = 3.5 Hz, 6H), 2.49 (d, J = 15.3 Hz, 1H), 2.08 (s, 3H), 2.05‐1.95 (m,
3H), 1.89 (s, 6H), 1.84 (ddd, J = 7.9, 6.0, 2.3 Hz, 1H), 1.79‐1.63 (m,
3H), 1.56‐1.40 (m, 4H), 1.34 (d, J = 29.4 Hz, 3H), 1.28‐1.20 (m, 9H),
1.16 (t, J = 6.6 Hz, 3H), 1.14‐1.09 (m, 6H), 1.07 (d, J = 7.5 Hz, 3H),
0.99 (dd, J = 13.7, 6.9 Hz, 3H), 0.88 (q, J = 7.5 Hz, 3H).

13

2.2 | Antibiotic activity
The minimum inhibitory concentration (MIC) displays the relative

C NMR

antibiotic potency of AZM and each derivative against a common

(101 MHz, Methanol‐d4) δ 178.13, 170.68, 170.67, 101.68, 101.59,

strain of bacteria (Staphylococcus aureus). The protocol used for the

96.21, 95.13, 76.53, 74.67, 74.56, 74.24, 73.79, 72.99, 72.95, 69.64,

determination of the MIC was as previously described with minor

67.15, 66.73, 65.33, 65.12, 64.63, 63.05, 62.94, 48.75, 48.73, 45.13,

modifications. 24 Staphylococcus aureus subsp aureus Rosenbach

41.78, 38.72, 35.52, 30.25, 25.45, 25.31, 22.41, 20.73, 20.58, 20.35,

(ATCC 6538) were grown in 5 mL of BactoTM Tryptic Soy Broth me‐

20.14, 19.44, 19.39, 17.08, 16.96, 15.96, 14.10, 10.09, 10.08. MS (ESI)

dium for 16 hours at 37°C with shaking (250 rpm) when an aliquot

m/z: [M + H]+ calcd for C42H77N2O14 834.5, found 834.5.

was diluted X1000 into 4.5 mL of fresh medium and incubated until

AZM7: AZM (2.0 mmol) was dissolved into 80 mL anhydrous

OD600 reaching 0.4. An aliquot of the suspension was diluted X1000.

ethyl acetate. 3.76 mL (40.0 mmol) of acetic anhydride and 4‐di‐

An aliquot (90 μL) was transferred into an individual well of a 96‐

methylaminopyridine (0.20 mmol) were added. After stirring at

well plate supplied with 5 μL of the test compound or control (AZM).

room temperature for 12 hours, the mixture was washed twice

Maximum final concentration of 1000 μmol/L with serial dilutions

with NaHCO3 (5% in water, 30 mL), and the organic phase was

was used to measure the antistaphylococcal activity in comparison

dried under vacuum. The product was purified by flash column

with the negative control (1% DMSO). The culture plates were in‐

chromatography with silica gel (DCM/MeOH) to give AZM6

cubated at 37°C for 16 hours with shaking (50 rpm). The OD600 of

(1.64 mmol). AZM6 (1.0 mmol) was dissolved into 40 mL of meth‐

each well measured using BioTek™ Synergy™ (Biotek, Winooski, VT)

anol containing 1% of conc. HCl, and the solution was stirred at

2 Multi‐Mode Microplate Readers. The acquired OD600 values were

room temperature for 16 hours Saturated NaHCO3 solution was

normalized to the negative control wells (100% viability). Resazurin

added to neutralilze the solution, and the solvent was removed

solution (5 μL) was also added to each well, and the plates were

under vacuum. The product was purified by flash column chro‐

shaken for 10 seconds and incubated at 37°C for another 3 hours

1

matography on silica gel (EtOAc/MeOH) to give 0.34 g AZM7. H

to allow resazurin to convert to resorufin by viable bacteria. The

NMR (400 MHz, Chloroform‐d) δ 4.96 (d, J = 5.6 Hz, 1H), 4.85 (dd,

minimal concentration of the tested compound that caused growth

J = 10.6, 2.6 Hz, 1H), 4.79 (dd, J = 10.5, 7.6 Hz, 1H), 4.75‐4.67 (m,

inhibition was recorded. The calculated MICs are shown in Table 1.
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F I G U R E 1 Altering the antibiotic properties of azithromycin does not decrease macrophage viability. Bone marrow‐derived macrophages
(BMDMs) were isolated from adult mice and were treated with AZM, AZM1, AZM4, AZM5, and AZM7 at concentrations of 1, 5, 25, and
125 μmol/L for 24 h Cell viability was measured by using MTT assay. AZM or AZM derivatives exhibited no cytotoxicity at any tested
concentration as compared to unstimulated, nontreated BMDM control (dotted line). Moreover, AZM and AZM derivatives at 25 and/or
125 μmol/L significantly increased proliferation of BMDMs as compared to unstimulated controls at *P < 0.05, **P < 0.01, ***P < 0.001. Data
are mean ±SD and representative of three independent biological replicate experiments

2.3 | Preparation of bone marrow‐derived
macrophages (BMDMs) and macrophage‐conditioned
medium (MCM)

of stimulation. Unstimulated BMDMs maintained in N2A growth
medium were used as control. Six hours following incubation, the su‐
pernatant of the stimulated macrophages (macrophage‐conditioned
media (MCM)) was collected and centrifuged to remove the cell de‐

BMDMs were isolated from the femurs and tibias of C57BL/6 mice

bris. The resulting media was either applied to Neuro‐2a cells for the

at 10‐16 weeks of age. In a tissue culture hood, the bones were

measurement of neurotoxicity or tested for IL‐10 and IL‐12p40 levels

flushed with a syringe filled with cold washing media (RPMI 1640

using standard ELISA kits (Thermo Scientific, Rockford, IL).

supplemented with 10% FBS and 1% penicillin/streptomycin) to ex‐
trude bone marrow into a sterile falcon tube. The bone marrow was
then triturated three times using syringes fit with 18 gauge needles
and then centrifuged at 1000 rpm for 5 minutes at 4°C. After remov‐
ing supernatant, red blood cells were lysed in lysis buffer (0.15 mol/L

2.4 | Assessment of macrophage and neuron
cell viability
BMDMs seeded in 96‐well plates (1 × 106 cells/mL) were treated

NH4Cl, 10 mmol/L KHCO3, and 0.1 mmol/L Na2EDTA, pH 7.4) for

with a range of concentrations (1‐125 μmol/L) of AZM or AZM de‐

3 min. The remaining cells were washed once in washing media and

rivatives for 24 hours Neuro2a (N2a) cell line is a generous gift from

then centrifuged at 212 g for 5 minutes at 4°C. The resulting cell

Chris Richards at the University of Kentucky. Cells were cultured in

pellet was resuspended in BMDM culture media (RPMI 1640 supple‐

N2a growth media, which contains 45% DMEM and 45% Opti‐MEM

mented with 1% penicillin/streptomycin, 1% HEPES, 0.001% β‐mer‐

Reduced‐Serum Medium (Life Technologies) supplemented with

captoethanol, 10% FBS, and 20% supernatant from sL929 cells) and

10% FBS and 1% penicillin/streptomycin. 26 Experiments were car‐

then plated in T75 flasks at a density of 1 × 106 cells/mL. The sL929

ried out using N2a cells within 12 passages. To test the neurotoxic‐

cell supernatant (cells, a generous gift from Phillip Popovich at The

ity of MCM, N2a cells were seeded in 96‐well plates at a density of

Ohio State University) contains macrophage colony stimulating fac‐

2 × 105 cells/mL for 24 hours in the growth media and then incu‐

tor, which is needed to promote differentiation of bone marrow cells

bated in MCM for another 24 hours The cell viability of BMDMs or

into macrophages. 25 Cell culture media was changed on days 2, 4,

N2a cells was measured by using MTT assay according to the manu‐

6

and 6, and then, cells were replated at the density of 1 × 10 cells/mL

facturer instructions and as described previously (Sigma‐Aldrich).7

on day 7 for designated stimulation and/or azithromycin (AZM) treat‐
ment. The following day, BMDMs were stimulated to be M1 using
LPS (50 ng/mL; Invivogen) plus IFN‐gamma (20 ng/mL; eBioscience)

2.5 | Statistical analyses

diluted in N2A growth medium as previously described.7 AZM (Sigma

Results are expressed as mean ± standard deviation (SD) and analyzed

PHR1088) or AZM derivatives were diluted to the concentrations of

using GraphPad Prism 6.0 (GraphPad Software). Data were compared

1, 5, 25, and 125 μmol/L and then added to the BMDMs at the time

by one‐way analysis of variance (ANOVA) among groups followed by

596

|

ZHANG et al.

F I G U R E 2 Nonantibiotic macrolides polarize proinflammatory macrophages to an anti‐inflammatory phenotype. BMDMs were
polarized to be M1 macrophages by stimulating with LPS +INF‐gamma. AZM, AZM1, AZM4, AZM5, and AZM7 were coapplied to M1
cells at concentrations of 1, 5, 25, and 125 μmol/L for 6 h Protein levels of IL‐12 (A) and IL‐10 (B) in cell culture medium were analyzed by
ELISA and expressed as fold change over M1 of mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs M1. Data are representative of three
independent biological replicate experiments. Each experiment was performed in triplicates per treatment group. (A) AZM and AZM 5 at the
concentrations of 25 and 125 μmol/L significantly decreased proinflammatory cytokine IL‐12, while AZM 4 and AZM 7 significantly reduced
IL‐12 level only at the concentration of 125 μmol/L. AZM 1 showed no effect in changing IL‐12 secretion. (B) The anti‐inflammatory cytokine
IL‐10 level was significantly increased in M1 macrophages coincubated with AZM and AZM 5 at the concentrations of 25 and 125 μmol/L;
while AZM 1, AZM 4, and AZM 7 significantly increased IL‐10 expression only at the highest tested concentration of 125 μmol/L (B)
Dunnett's or Holmes‐Sidak multiple comparison tests. Differences

macrophage response in vivo. When stimulated with LPS+IFN‐gamma),

were determined to be statistically significant at P value ≤0.05.

BMDMs model proinflammatory macrophages found in neuropatholo‐
gies.2,8,19 No doses of AZM or its derivatives were toxic to BMDMs

3 | R E S U LT S
3.1 | Assessment of macrophage viability

when applied directly to the cells for 24 hours (Figure 1). Interestingly,
this prolonged stimulation of BMDMs with high doses of AZM and its
derivatives resulted in increased readouts on the MTT assay indicative of
increased BMDM proliferation or increased metabolic activity (Figure 1).

We chose to use primary bone marrow‐derived macrophages (BMDMs)

This effect was not as robust after 6 hours of stimulation (Figure S8), and

for our studies as BMDM responses in vitro are predictive of CNS

therefore, a 6‐hr stimulation time point was used for subsequent assays.

|
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F I G U R E 3 Nonantibiotic macrolides decrease the neurotoxic potential of proinflammatory macrophages. Neuron 2A (N2A) cells were
incubated with MCM for 24 h MCM from M1 macrophages reduced neuron cell viability significantly as compared to control (N2a cells
treated with MCM from unstimulated, nontreated BMDMs, dotted line), M1 vs Control at $$$$P < 0.0001). MCM from M1 macrophages
coincubated with AZM and/or AZM 4, AZM 5, and AZM 7 at 25 and/or 125 μmol/L restored neuron cell viability as compared to M1 MCM
(*P < 0.05, P < 0.01, P < 0.0001 vs M1). Derivative AZM 1 exhibited no effect in modulating M1 MCM‐induced neurotoxicity. Data are
mean ± SD and representative of three independent biological replicate experiments

3.2 | Macrophage IL‐12/IL‐10 levels with derivatives

analyses of select genes associated with M1 or M2 macrophage
phenotypes (ie, IL‐6, IL‐1b, TNF‐a, and TGF‐b) demonstrated simi‐

The relative expression of IL‐10 and IL‐12 is a defining feature of M1

lar immunomodulatory effects between AZM and derivatives 4 and

and M2 macrophages27 with M2 macrophages producing high levels

7 (Figure S9). Collectively, these data demonstrate that altering the

of IL 10 and low levels of IL‐12. Conversely, M1 macrophages pro‐

bacterial binding residues of AZM does not reduce its immunomod‐

duce substantial amounts of IL‐12 and minimal IL‐10. These cytokine

ulatory properties with AZM5 having similar dose‐response proper‐

profiles are also predictive of the neurotoxic potential of stimulated

ties as the parent compound.

macrophages with toxic potential decreasing with increased IL‐10
and reduced IL‐12 production.7,28 Similar to previous observations,6,7
AZM reduced production of the proinflammatory cytokine, IL‐12,
and elevated the secretion of the anti‐inflammatory cytokine IL‐10 in

3.3 | Macrophage‐mediated neurotoxicity with
derivatives

M1 macrophages in a dose‐dependent manner 6 hours after stimu‐

We previously reported that M1 supernatant, that is, macrophage‐

lation. Compared to M1‐stimulated macrophages, costimulation of

conditioned medium (MCM), is neurotoxic when applied to neuron

M1 stimulant (LPS +IFN‐gamma) with either 25 or 125 μmol/L AZM

cells and treatment of M1 macrophages with AZM significantly al‐

significantly decreased IL‐12 (P < 0.01 and <0.001, respectively) and

leviates this neurotoxic effect. 2,7 Since we have observed similar ef‐

increased IL‐10 (P < 0.01 and <0.0001, respectively; Figure 2).

fects of M1 MCM on both primary neurons and the neuro2A cell

To determine the immunomodulatory properties of our azi‐

line, 2,7 we chose to evaluate the neurotoxic potential of AZM and

thromycin derivatives, we examined IL‐10 and IL‐12 production in

derivatives using neuro2a (N2A) cells. Consistent with these previ‐

BMDMs costimulated with derivatives and M1 stimulants (LPS +

ous observations, M1 MCM significantly reduced N2A cell viability

INF‐gamma). We detected significantly decreased IL‐12 produc‐

(P < 0.0001 vs N2A cells incubated with unstimulated/untreated

tion with 125 μmol/L cotreatment concentrations for derivatives

MCM; Figure 3). MCM generated by BMDM costimulation with LPS

4 (P < 0.001) and 7 (P < 0.05) relative to M1 stimulation alone

+ INF‐gamma and AZM (25 and 125 μmol/L) significantly reversed

(Figure 2). Derivative 5 had significantly reduced IL‐12 production

the MCM toxicity (25 μmol/L P < 0.0001; 125 μmol/L P < 0.05 vs

with 25 μmol/L (P < 0.01) and 125 μmol/L (P < 0.0001) concentra‐

M1; Figure 3). Direct application of AZM on N2A cells had no effect

tions. There was no significant effect on IL‐12 with derivative 1. We

on cell viability, and MCM isolated from BMDMs treated with AZM

observed reciprocal significant increases in IL‐10 with all derivatives

in the absence of M1 stimulants had no effect on neuron viability

at the highest dose of 125 μmol/L (P < 0.05, Figure 2). In addition,

(Figure 3).

the 25 μmol/L stimulation with derivative 5 significantly increased

AZM5 was the most comparable to AZM in alleviating neuro‐

production of IL‐10 relative to M1 (P < 0.001; Figure 2). RT‐PCR

toxicity of M1‐stimulated BMDMs, with concentrations of 25 and
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125 μmol/L both showing significant neuroprotective effects

tested. Interestingly, however, AZM7 did not retain any antistaph‐

(P < 0.01 and P < 0.0001, respectively, vs M1). Derivatives AZM4

ylococcal activity. Similarly, AZM4, which also lacks the cladinose

and AZM7 at the concentration of 125 μmol/L also significantly

that is replaced by a carbonyl, had modest yet significant immu‐

attenuated the neurotoxic effect of M1 MCM (P < 0.0001 vs M1).

nomodulatory effects with minimal antistaphylococcal activity.

Contrastingly, AZM1 did not significantly decrease M1 MCM‐in‐

Although AZM1 at the concentration of 125 μmol/L significantly

duced neurotoxicity at any tested concentrations.

increases IL‐10 level, it has no effect in reducing IL‐12 production.
Interestingly, AZM1 also induced significant but small changes,
relative to AZM, in BMDM metabolic activity at this high dose.

4 | D I S CU S S I O N

AZM5, which was the only derivative tested without the cladi‐
nose removed, closely mimicked or slightly exceeded AZM's ac‐

In this study, we demonstrate the retention of immunomodulatory

tivity at all concentrations tested including the BMDM MTT assay.

activity in AZM derivatives with altered sugar moieties using ourin

Unfortunately, the acetylation of both sugars in AZM5 did not

vitro model of macrophage CNS inflammation. This model accu‐

abolish the antistaphylococcal activity as desired. This may sug‐

rately predicts the macrophage/microglial response in the injured

gest, however, that chemical modifications to substitute the cla‐

CNS.7,8,19,20 Specifically, we demonstrate that these derivatives,

dinose with functional variants may be an effective approach in

like the AZM parent compound, have no negative toxic effects on

developing subsequent generations of derivatives. Future studies

macrophage viability, retain the ability to polarize M1 macrophages

that systematically alter each of these components may better

toward the M2 phenotype as determined by IL‐10/12 cytokine pro‐

clarify which of these modifications are beneficial or detrimental

files, and are equally effective in reducing the neurotoxic effects

in retaining/improving AZM's immunomodulatory activity.

of M1 macrophage supernatants on neuronal cultures. In these

We demonstrated the clear anti‐inflammatory activity of these

studies, the ability of the derivatives to shift IL‐10/12 cytokine

AZM derivativesin vitro; however, related studies utilizing derivatives

profiles closely correlated with their ability to mitigate M1 super‐

of AZM and other macrolides suggest that these drug candidates likely

natant toxicity to neurons. This supports our notion of utilizing

hold great potential for treating inflammatory disorders of the CNS in

IL‐10/12 cytokine profiles as an indicator of M1/M2 macrophage

vivo. For example, Sugawara et. al (2012) developed a series of anti‐in‐

polarization and neurotoxicity. Recent literature demonstrates that

flammatory nonantibiotic macrolide derivatives in vitro and then suc‐

AZM increases reparative macrophage activation in rodent mod‐

cessfully used these derivatives in an in vivo model of inflammatory

els of spinal cord injury, stroke, lung infection, skin inflammation,

bowel disease.14 Together with our prior work demonstrating the pre‐

This anti‐inflammatory

dictive nature of our in vitro model,7,8,19,20 these results suggest that

mechanism, potentially unrelated to AZM's antibacterial properties,

our compounds hold great promise in treating the detrimental neuroin‐

holds great promise in the treatment of these diverse inflammatory

flammatory conditions. Given that there are extremely few treatment

conditions.

options for most neurological disorders, our current findings clearly

and in humans with cystic fibrosis.

7-12,29-31

Further, this relatively unexplored therapeutic approach could
likely be exploited more effectively with continued optimization

demonstrate the importance of these drugs and support their contin‐
ued development into novel therapeutics to treat CNS inflammation.

of therapeutics such as AZM and related macrolides. In particular,

While the current study and related publications show encourag‐

one major obstacle in the clinical development of anti‐inflammatory

ing therapeutic outcomes following stimulations with derivatives of

macrolide antibiotics, such as AZM, is the concern that increased

AZM and other macrolides, the exact mechanisms of action remain

use of these drugs for their secondary anti‐inflammatory effects

uncertain. Much of the work in this regard has converged in identify‐

may inadvertently promote bacterial resistance to this antibiotic

ing the NF‐κB signaling cascade as the core regulator of the observed

in the treatment of a variety of infections. In the spinal cord injury

shifts in cytokine profiles following macrolide treatment. 29,33-35

patient population, for example, AZM is the antibiotic of choice for

While this is clearly important, the molecular target upstream of

treating recurrent respiratory infections and pneumonia,32 a leading

the NF‐κB cascade on which these drugs act remains unclear.36 In

cause of death following spinal cord injury; thus, antibiotic resis‐

vitro studies show that AZM accumulates in macrophage lysosomes,

tance is a major concern. Fortunately, recent studies have indicated

where it increases the pH, interacts with membrane lipids, induces

that macrolides modified to remove their antibacterial activity retain

phospholipidosis, and alters vesicular trafficking which may affect

beneficial anti‐inflammatory effects in models of inflammatory skin

endocytosis and phagocytosis.37,38 Other suggested mechanisms

disorders and chronic lung diseases.13,16

indicate that AZM may alter cellular autophagy, or alter the TLR4

Collectively, we demonstrate that AZM derivatives with al‐

signaling pathways by changing endosome trafficking.37 Further,

tered sugar moieties retain immunomodulatory properties. We

it remains unknown whether these findings remain valid in vivo

did not, however, observe uniform immunomodulatory and neu‐

or whether derivatives of AZM retain the same mechanism of ac‐

roprotective properties with all derivatives tested. AZM7, which

tion. While complicated, continued work in these areas is essential

had the most extensive chemical modifications (diacetylation

as it could lead to new therapeutics, such as the compounds de‐

and the removal of the cladinose moiety), invoked modest immu‐

scribed here, or provide novel therapeutic targets for future drug

nomodulatory effects exclusively at the highest concentration

development.
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One interesting finding in the current study was the fairly pro‐
nounced increase in macrophage viability when treated with the high‐
est dose of AZM or derivative for 24 hours (widely used time point
for measuring drug toxicity in vitro). This assay measures the conver‐

3.

sion of tetrazolium dye MTT 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphen‐
yltetrazolium bromide to formazan by NAD(P)H‐dependent cellular
oxidoreductase enzymes, and this measure of metabolic activity is

4.

routinely used to quantify changes in cell number or vitality. How AZM
and its derivatives induce this effect at high concentrations, and how
this may alter inflammatory activities remains unclear, however, it is

5.

unlikely that this is directly related to our observed shifts in cytokine
profiles and neurotoxicity across drug concentrations. If the observed
increases in IL‐10 following AZM stimulations were simply a result of
cellular proliferation, then IL‐12 would also be expected to rise, instead,
however, IL‐12 levels fell dramatically. Similarly, measurements of cel‐

6.

7.

lular proliferation/metabolism at the 6‐hour time point, when we mea‐
sure IL‐10/12 levels, displayed more modest increases in proliferation/
metabolism and are thus less likely to influence our cytokine profiles.

8.

In conclusion, we have identified AZM derivatives that retain
key immunomodulatory functions in our in vitro model of CNS
inflammation. While the antiinfective properties of the deriva‐
tives were associated with neuroprotection, we also observed
that some derivatives with greatly reduced antiinfective charac‐
teristics retained neuroprotective and anti‐inflammatory func‐

9.

10.

tions. Although a limited sample size of derivatives was created
and tested, this indicates that the antibiotic properties of AZM
may not be required for immunomodulatory‐mediated neuropro‐
tection. With continued development, these compounds could

11.

become viable clinical neuroprotectants and immunomodulatory
treatments for neuropathologies. Additionally, given the usage
of AZM's anti‐inflammatory properties across disciplines, these

12.

drugs hold great potential in treating a wide variety of inflamma‐
tion‐based human disorders.
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